MelCancerVac (ENOB-DB-01)
/ Renovaro Biosci
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
May 24, 2022
Melanoma-specific antigen-associated antitumor antibody reactivity as an immune-related biomarker for targeted immunotherapies.
(PubMed, Commun Med (Lond))
- "Here, we applied the next generation phage display mimotope variation analysis (MVA) to profile antibody response and dissect the role of humoral immunity in targeted cancer therapies, namely anti-tumor dendritic cell vaccine (MelCancerVac) and immunotherapy with anti-PD-1 monoclonal antibodies (pembrolizumab). The antibody epitopes as biomarkers reflect melanoma-associated features of immune response, and also provide insights into the molecular pathways contributing to the pathogenesis of cancer. Concluding, antibody epitope response can be useful in predicting anti-cancer immunity elicited by immunotherapy."
Biomarker • IO biomarker • Journal • Immune Modulation • Immunology • Inflammation • Lung Cancer • Melanoma • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1